Asset Details
Do you wish to reserve the book?
Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization
Do you wish to request the book?
Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Comparison of Rosuvastatin Versus Atorvastatin for Coronary Plaque Stabilization
2019
Overview
Statins are widely used to lower cholesterol and to reduce cardiovascular events. Whether all statins have similar effects on plaque stabilization is unknown. We aimed to investigate coronary plaque response to treatment with different statins that result in similar lipid reduction using serial multimodality intracoronary imaging. Patients with de novo coronary artery disease requiring intervention were randomized to rosuvastatin 10mg (R10) or atorvastatin 20mg (A20) daily. Optical coherence tomography and intravascular ultrasound were performed at baseline, 6 months, and 12 months. Untreated nonculprit plaques were analyzed by optical coherence tomography for thin-cap fibroatheroma, minimum fibrous cap thickness, lipid arc, and lipid length. Total and percent atheroma volume, respectively were analyzed by intravascular ultrasound. Forty-three patients completed the protocol (R10: 24 patients, 31 plaques; A20: 19 patients, 30 plaques). The decrease in serum lipids was similar. From baseline to 6 months to 12 months, minimum fibrous cap thickness increased in the R10 group (61.4 ± 15.9 µm to 120.9 ± 57.9 µm to 171.5 ± 67.8 µm, p <0.001) and the A20 group (60.8 ± 18.1 µm to 99.2 ± 47.7 µm to 127.0± 66.8 µm, p <0.001). Prevalence of thin-cap fibroatheroma significantly decreased in the R10 and A20 groups (−48% and −53%, respectively, p <0.001 for intragroup comparisons). Only the R10 group had a decrease in macrophage density (−23%, p = 0.04) and microvessels (−12%, p = 0.002). Total atheroma volume decreased in the R10 group (109.2 ± 62.1 mm3 to 101.8 ± 61.1 mm3 to 102.5 ± 62.2 mm3, p = 0.047) but not in the A20 group (83.3 ± 48.5mm3 to 77.6 ± 43.0 mm3 to 77.9 ± 48.6 mm3, p = 0.07). In conclusion, although both statins demonstrated similar reductions in lipid profiles, the rosuvastatin group showed more rapid and robust plaque stabilization, and regression of plaque volume compared to the atorvastatin group.
Publisher
Elsevier Inc,Elsevier BV,Elsevier Limited
Subject
/ Atorvastatin - therapeutic use
/ Coronary Artery Disease - blood
/ Coronary Artery Disease - diagnosis
/ Coronary Artery Disease - drug therapy
/ Coronary Vessels - diagnostic imaging
/ Female
/ Humans
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors
/ Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
/ Lipids
/ Male
/ Optical Coherence Tomography
/ Patients
/ Plaque, Atherosclerotic - blood
/ Plaque, Atherosclerotic - diagnosis
/ Plaque, Atherosclerotic - drug therapy
/ Plaques
/ Rosuvastatin Calcium - therapeutic use
/ Statins
/ Tomography, Optical Coherence
/ Tomography, Optical Coherence - methods
/ Ultrasonography, Interventional
